Breast CancerE3NNCT03285230
The French E3N Prospective Cohort Study
An observational study of Breast Cancer and Colo-rectal Cancer, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.
Trial summary
The French E3N cohort was initiated in 1990 to investigate the risk factors associated with cancer and other major non-communicable diseases in women. The participants were insured through a national health system that primarily covered teachers, and were enrolled from 1990 after returning baseline self-administered… Read more about this study
- Who is it for?
- Ages 40 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Breast Cancer, Colo-rectal Cancer, Parkinson Disease
- How many people
- 100,000 participants
- Where
- 1 siteFrance
- Study dates
- 15 Jun 1990to 31 Dec 2046
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: The cohort comprised nearly 100 000 women with baseline ages ranging from 40 to 65 years, all insured through a French national health system (MGEN).
Who may be able to join
- only women
- born between 1925 and 1950
- insured by the Mutuelle Générale de l'Education Nationale (MGEN)
Who cannot join
- men
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The French E3N Prospective Cohort Study (Etude Epidémiologique auprès de Femmes de la Mutuelle Générale de l'Education Nationale)
The French E3N cohort was initiated in 1990 to investigate the risk factors associated with cancer and other major non-communicable diseases in women.
The participants were insured through a national health system that primarily covered teachers, and were enrolled from 1990 after returning baseline self-administered questionnaires and providing informed consent. The cohort comprised nearly 100 000 women with baseline ages ranging from 40 to 65 years.
Read more
Follow-up questionnaires were sent approximately every 2-3 years after the baseline and addressed general and lifestyle characteristics together with medical events (cancer, cardiovascular diseases, diabetes, depression, fractures and asthma, among others). The follow-up questionnaire response rate remained stable at approximately 80%.
A biological material bank was generated and included blood samples collected from 25 000 women and saliva samples from an additional 47 000 women.
Ageing among the E3N cohort provided the opportunity to investigate factors related to agerelated diseases and conditions as well as disease survival.
Read the detailed description
Who is in the cohort? In June 1990, a questionnaire was sent to 500 000 women who had been born between 1925 and 1950 and were insured by the Mutuelle Générale de l'Education Nationale (MGEN), a national health insurance plan that primarily covers teachers. The questionnaire was sent along with a leaflet explaining that an Inserm research team was launching a study of cancer risk factors and that participation would require filling in questionnaires every 2-3 years as well as the submission of a signed consent form providing permission to obtain information about each participant's vital status, address changes and medical expense reimbursements from the insurance plan. Nearly 100 000 women volunteered.
How often have they been followed-up? Until now, nine follow-up questionnaires have been sent every 2-3 years from the baseline. Approximately half of the answers were obtained after the first mailing. Two reminders were sent thereafter. The questionnaires were accompanied with newsletters that informed participants about the major results obtained to date. The participation rate remained high (77-92% according to the questionnaires) and the lost to follow-up rate was minimal because of the ability to trace non-respondents through their insurance plan files. The questionnaires were accurately filled in, with few missing or unacceptable answers.
What has been measured? To date, 11 self-administered questionnaires have been sent. The collected data are sociodemographic factors, anthropometric measurements, reproductive factors, hormonal treatments, health behaviour and lifestyle. Each follow-up questionnaire also recorded the participant's health status. The questionnaires are available at www.e3n.fr .
The questionnaires are anonymous and identified with an identification number and pin code that can be rapidly scanned to identify the respondents. The questionnaires are optically scanned and all answers are checked on screen. The scanned images are saved to allow data entry at a later time, including information regarding the addresses of medical doctors (18 000 to date) or drug names (pre-listed to avoid errors). The longitudinal data (repeats of identical questions for the purpose of updating information about topics such as menopause or smoking) are routinely homogenized. Several validation studies (e.g. dietary and anthropometrical data studies) have been performed and have revealed very satisfactory results.
Self-reported cases of cancer are validated and coded after reviewing the pathology reports obtained from medical practitioners, and nearly 90% of all cancer cases are histologically confirmed. Other diseases are also validated (e.g. diabetes, myocardial infarction, stroke, Parkinson disease) by requesting additional information about the participants (e.g. glycosylated haemoglobin levels, fracture-related circumstances, drug names) and sending questionnaires to medical doctors.
Additionally, a biological material bank was generated. Blood samples were initially collected from 1994-99. The participation rate among the invited participants was approximately 40%; this yielded approximately 25 000 blood samples that were each separated into 28 aliquots (e.g. plasma, serum, leukocytes, erythrocytes). Plastic straws were used to store each participant's samples in liquid nitrogen containers. The bio-repositories are located at the IARC (Lyon) and the EFS (Etablissement Français du Sang, Annemasse). Since 2004, approximately 10 case-control studies have been conducted (approximately 1 800 cases and 3 500 controls) with regard to the measurements of various biomarkers (e.g. fatty acids, calcium, vitamin D, vitamin B, cholesterol and C-reactive protein). A metabolomics study is currently ongoing.
From 2009-11, saliva samples (Oragene, DNA Genotek, Kanata, ON, Canada) were requested from 68 242 living women and were obtained from 47 000 women (participation rate, 69%). Salivary DNA has been extracted and has been used for genotyping in two case-control studies (approximately 2 500 cases and 850 controls) since December 2010.
The research team is currently planning to set up a tumour tissue bank and will begin with the collection of breast cancer tissues.
What has it found? The E3N cohort has produced a spectrum of results regarding the complex roles played by nutrition, hormonal factors, physical activity, anthropometric characteristics and other major lifestyle-related factors with respect to various diseases.
- Conditions
- Breast Cancer, Colo-rectal Cancer, Parkinson Disease, Asthma, Diabetes, Inflammatory Bowel Diseases
- Medical subject headings
- Breast Neoplasms, Colonic Neoplasms, Parkinson Disease, Asthma, Diabetes Mellitus, Inflammatory Bowel Diseases, Melanoma, Endometriosis
What is being measured
The primary outcome is the main question the study is designed to answer.
Anthropometric measurements
Height, weight, hip circumference and waist circumference
Measured: From 1990 until now
Educational level
Measured: 1990
Professional activity
Insee categories
Measured: 1992 and 2005
Age at cessation of activity
Measured: From 2005 until now
Menstrual factors
Age at menarche, length of menstrual cycle
Measured: From 1990 to 2002
Reproductive history
Number of pregnancies, age at each pregnancy, durations and outcomes of pregnancies, breastfeeding, infertility
Measured: From 1990 to 1992
Menopause
Age, type
Measured: 1990, 1995, 1997, 2000, 2002, 2005
Hormonal Treatments
Menopausal Hormonal Treatments (MHT), oral contraceptives
Measured: From 1992 to 2008
Tobacco consumption
Type, quantity, time of smoking
Measured: From 1990 until now
Alcohol consumption
Type of alcohol, quantity
Measured: 1993, 1997, 2005
Physical activity
Moderate and intense activity, sedentarity
Measured: 1990,1997,2002, 2005, 2014
Diet questionnaire
Precise annual diet questionnaire
Measured: 1993 and 2002
Family history of diseases
Cancer, diabetes and cardiovascular diseases
Measured: 1990 to 2005
Medication use
linked with the drug reimbursement files from the health insurance
Measured: From 1990 until now
Medical and surgical history
Measured: From 1990 until now
Mental Health
Centre for Epidemiologic Studies Depression Scale (CESD) and Depression
Measured: From 1990 until now
Health outcomes
Measured: From 1990 until now
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2017
- Study start15 Jun 1990
- Primary completion15 Nov 1991
- Study completion31 Dec 2046 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (21)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Institut National de la Santé Et de la Recherche Médicale, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100,000 participants (actual)
Sponsor and investigators
- Sponsor type
- Other government
- Collaborators
- Université Paris-Sud, Gustave Roussy, Cancer Campus, Grand Paris, Ligue contre le cancer, France
- Responsible party
- Sponsor
- Investigators
- Gianluca Severi, PhD, Study director, INSERM (Institut National de la Sante et de la Recherche Medicale)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03285230
- Sponsor's protocol ID
- C 95-01
- Acronym
- E3N
- Status last verified
- Jun 2026
- First submitted
- 27 Jul 2017
- Last updated
- 25 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Clavel-Chapelon F; E3N Study Group. Cohort Profile: The French E3N Cohort Study. Int J Epidemiol. 2015 Jun;44(3):801-9. doi: 10.1093/ije/dyu184. Epub 2014 Sep 10.
PubMed 25212479Danjou AMN, Coudon T, Praud D, Leveque E, Faure E, Salizzoni P, Le Romancer M, Severi G, Mancini FR, Leffondre K, Dossus L, Fervers B. Long-term airborne dioxin exposure and breast cancer risk in a case-control study nested within the French E3N prospective cohort. Environ Int. 2019 Mar;124:236-248. doi: 10.1016/j.envint.2019.01.001. Epub 2019 Jan 16.
PubMed 30658268Lajous M, Boutron-Ruault MC, Fabre A, Clavel-Chapelon F, Romieu I. Carbohydrate intake, glycemic index, glycemic load, and risk of postmenopausal breast cancer in a prospective study of French women. Am J Clin Nutr. 2008 May;87(5):1384-91. doi: 10.1093/ajcn/87.5.1384.
PubMed 18469262Fournier A, Cairat M, Severi G, Gunter MJ, Rinaldi S, Dossus L. Use of menopausal hormone therapy and ovarian cancer risk in a French cohort study. J Natl Cancer Inst. 2023 Jun 8;115(6):671-679. doi: 10.1093/jnci/djad035.
PubMed 36809347Paoletti X, Clavel-Chapelon F. Induced and spontaneous abortion and breast cancer risk: results from the E3N cohort study. Int J Cancer. 2003 Aug 20;106(2):270-6. doi: 10.1002/ijc.11203.
PubMed 12800205Clavel-Chapelon F; E3N-EPIC Group. Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br J Cancer. 2002 Mar 4;86(5):723-7. doi: 10.1038/sj.bjc.6600124.
PubMed 11875733Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005 Apr 10;114(3):448-54. doi: 10.1002/ijc.20710.
PubMed 15551359Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol. 2008 Mar 10;26(8):1260-8. doi: 10.1200/JCO.2007.13.4338.
PubMed 18323549Dusser P, Nguyen Y, Perrin C, Frenoy P, Mariette X, Boutron-Ruault MC, Severi G, Salliot C, Seror R. Birth length and perinatal exposures and rheumatoid arthritis risk in the E3N cohort. RMD Open. 2026 Apr 9;12(2):e006415. doi: 10.1136/rmdopen-2025-006415.
PubMed 41956708Dusser P, Nguyen Y, Perrin C, Frenoy P, Mariette X, Boutron-Ruault MC, Varraso R, Severi G, Salliot C, Seror R. Early-life animal and farming exposures and the risk of rheumatoid arthritis: findings from the E3N French cohort study. RMD Open. 2025 Dec 7;11(4):e005954. doi: 10.1136/rmdopen-2025-005954.
PubMed 41360603Auguste A, Jansana A, Freisling H, Ferrari P, Laouali N, Severi G, Kvaskoff M. Impact of Hypertension on Cancer Stage at Diagnosis Among French Women: The E3N Prospective Cohort. Cancer Med. 2025 Aug;14(15):e71021. doi: 10.1002/cam4.71021.
PubMed 40719276Klu YE, Amazouz H, Canonico M, Guenel P, Kvaskoff M, Severi G, Radoi L, Auguste A. Association Between Hormonal Factors and Risk of Lung and Upper Aerodigestive Tract Cancer in French Women: The E3N Prospective Cohort Study. Cancer Rep (Hoboken). 2025 Jun;8(6):e70223. doi: 10.1002/cnr2.70223.
PubMed 40490966Koemel NA, Shah S, Senior AM, Severi G, Mancini FR, Gill TP, Simpson SJ, Raubenheimer D, Boutron-Ruault MC, Laouali N, Skilton MR. Macronutrient composition of plant-based diets and breast cancer risk: the E3N prospective cohort study. Eur J Nutr. 2024 Aug;63(5):1771-1781. doi: 10.1007/s00394-024-03379-x. Epub 2024 Apr 18.
PubMed 38635026Shah S, Mahamat-Saleh Y, Ait-Hadad W, Koemel NA, Varraso R, Boutron-Ruault MC, Laouali N. Long-term adherence to healthful and unhealthful plant-based diets and breast cancer risk overall and by hormone receptor and histologic subtypes among postmenopausal females. Am J Clin Nutr. 2023 Mar;117(3):467-476. doi: 10.1016/j.ajcnut.2022.11.019.
PubMed 36872016Shah S, Mahamat-Saleh Y, Hajji-Louati M, Correia E, Oulhote Y, Boutron-Ruault MC, Laouali N. Palaeolithic diet score and risk of breast cancer among postmenopausal women overall and by hormone receptor and histologic subtypes. Eur J Clin Nutr. 2023 May;77(5):596-602. doi: 10.1038/s41430-023-01267-x. Epub 2023 Feb 1.
PubMed 36726032
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The French E3N Prospective Cohort Study (Etude Epidémiologique auprès de Femmes de la Mutuelle Générale de l'Education Nationale)
- ClinicalTrials.gov ID
- NCT03285230
- Acronym / sponsor ID
- E3N / C 95-01
- Conditions
- Breast Cancer, Colo-rectal Cancer, Parkinson Disease, Asthma, Diabetes, Inflammatory Bowel Diseases
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 100,000 participants (actual)
- Lead sponsor
- Institut National de la Santé Et de la Recherche Médicale, FranceOther government
- Collaborators
- Université Paris-Sud, Gustave Roussy, Cancer Campus, Grand Paris, Ligue contre le cancer, France
- Study start
- 15 Jun 1990 (actual)
- Primary completion
- 15 Nov 1991 (actual)
- Study completion
- 31 Dec 2046 (estimated)
- First posted
- 15 Sep 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The French E3N cohort was initiated in 1990 to investigate the risk factors associated with cancer and other major non-communicable diseases in women.
The participants were insured through a national health system that primarily covered teachers, and were enrolled from 1990 after returning baseline self-administered questionnaires and providing informed consent. The cohort comprised nearly 100 000 women with baseline ages ranging from 40 to 65 years.
Follow-up questionnaires were sent approximately every 2-3 years after the baseline and addressed general and lifestyle characteristics together with medical events (cancer, cardiovascular diseases, diabetes, depression, fractures and asthma, among others). The follow-up questionnaire response rate remained stable at approximately 80%.
A biological material bank was generated and included blood samples collected from 25 000 women and saliva samples from an additional 47 000 women.
Ageing among the E3N cohort provided the opportunity to investigate factors related to agerelated diseases and conditions as well as disease survival.
Detailed description
Who is in the cohort? In June 1990, a questionnaire was sent to 500 000 women who had been born between 1925 and 1950 and were insured by the Mutuelle Générale de l'Education Nationale (MGEN), a national health insurance plan that primarily covers teachers. The questionnaire was sent along with a leaflet explaining that an Inserm research team was launching a study of cancer risk factors and that participation would require filling in questionnaires every 2-3 years as well as the submission of a signed consent form providing permission to obtain information about each participant's vital status, address changes and medical expense reimbursements from the insurance plan. Nearly 100 000 women volunteered.
How often have they been followed-up? Until now, nine follow-up questionnaires have been sent every 2-3 years from the baseline. Approximately half of the answers were obtained after the first mailing. Two reminders were sent thereafter. The questionnaires were accompanied with newsletters that informed participants about the major results obtained to date. The participation rate remained high (77-92% according to the questionnaires) and the lost to follow-up rate was minimal because of the ability to trace non-respondents through their insurance plan files. The questionnaires were accurately filled in, with few missing or unacceptable answers.
What has been measured? To date, 11 self-administered questionnaires have been sent. The collected data are sociodemographic factors, anthropometric measurements, reproductive factors, hormonal treatments, health behaviour and lifestyle. Each follow-up questionnaire also recorded the participant's health status. The questionnaires are available at www.e3n.fr .
The questionnaires are anonymous and identified with an identification number and pin code that can be rapidly scanned to identify the respondents. The questionnaires are optically scanned and all answers are checked on screen. The scanned images are saved to allow data entry at a later time, including information regarding the addresses of medical doctors (18 000 to date) or drug names (pre-listed to avoid errors). The longitudinal data (repeats of identical questions for the purpose of updating information about topics such as menopause or smoking) are routinely homogenized. Several validation studies (e.g. dietary and anthropometrical data studies) have been performed and have revealed very satisfactory results.
Self-reported cases of cancer are validated and coded after reviewing the pathology reports obtained from medical practitioners, and nearly 90% of all cancer cases are histologically confirmed. Other diseases are also validated (e.g. diabetes, myocardial infarction, stroke, Parkinson disease) by requesting additional information about the participants (e.g. glycosylated haemoglobin levels, fracture-related circumstances, drug names) and sending questionnaires to medical doctors.
Additionally, a biological material bank was generated. Blood samples were initially collected from 1994-99. The participation rate among the invited participants was approximately 40%; this yielded approximately 25 000 blood samples that were each separated into 28 aliquots (e.g. plasma, serum, leukocytes, erythrocytes). Plastic straws were used to store each participant's samples in liquid nitrogen containers. The bio-repositories are located at the IARC (Lyon) and the EFS (Etablissement Français du Sang, Annemasse). Since 2004, approximately 10 case-control studies have been conducted (approximately 1 800 cases and 3 500 controls) with regard to the measurements of various biomarkers (e.g. fatty acids, calcium, vitamin D, vitamin B, cholesterol and C-reactive protein). A metabolomics study is currently ongoing.
From 2009-11, saliva samples (Oragene, DNA Genotek, Kanata, ON, Canada) were requested from 68 242 living women and were obtained from 47 000 women (participation rate, 69%). Salivary DNA has been extracted and has been used for genotyping in two case-control studies (approximately 2 500 cases and 850 controls) since December 2010.
The research team is currently planning to set up a tumour tissue bank and will begin with the collection of breast cancer tissues.
What has it found? The E3N cohort has produced a spectrum of results regarding the complex roles played by nutrition, hormonal factors, physical activity, anthropometric characteristics and other major lifestyle-related factors with respect to various diseases.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 40 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The cohort comprised nearly 100 000 women with baseline ages ranging from 40 to 65 years, all insured through a French national health system (MGEN).
Key inclusion criteria (3 listed)
- only women
- born between 1925 and 1950
- insured by the Mutuelle Générale de l'Education Nationale (MGEN)
Key exclusion criteria (1 listed)
- men
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Anthropometric measurements
Time frame: From 1990 until now
Height, weight, hip circumference and waist circumference
Educational level
Time frame: 1990
Professional activity
Time frame: 1992 and 2005
Insee categories
Age at cessation of activity
Time frame: From 2005 until now
Menstrual factors
Time frame: From 1990 to 2002
Age at menarche, length of menstrual cycle
Reproductive history
Time frame: From 1990 to 1992
Number of pregnancies, age at each pregnancy, durations and outcomes of pregnancies, breastfeeding, infertility
Menopause
Time frame: 1990, 1995, 1997, 2000, 2002, 2005
Age, type
Hormonal Treatments
Time frame: From 1992 to 2008
Menopausal Hormonal Treatments (MHT), oral contraceptives
Tobacco consumption
Time frame: From 1990 until now
Type, quantity, time of smoking
Alcohol consumption
Time frame: 1993, 1997, 2005
Type of alcohol, quantity
Physical activity
Time frame: 1990,1997,2002, 2005, 2014
Moderate and intense activity, sedentarity
Diet questionnaire
Time frame: 1993 and 2002
Precise annual diet questionnaire
Family history of diseases
Time frame: 1990 to 2005
Cancer, diabetes and cardiovascular diseases
Medication use
Time frame: From 1990 until now
linked with the drug reimbursement files from the health insurance
Medical and surgical history
Time frame: From 1990 until now
Mental Health
Time frame: From 1990 until now
Centre for Epidemiologic Studies Depression Scale (CESD) and Depression
Health outcomes
Time frame: From 1990 until now
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2026.
- Background: PubMed 25212479Clavel-Chapelon F; E3N Study Group. Cohort Profile: The French E3N Cohort Study. Int J Epidemiol. 2015 Jun;44(3):801-9. doi: 10.1093/ije/dyu184. Epub 2014 Sep 10.
- Results publication: PubMed 30658268Danjou AMN, Coudon T, Praud D, Leveque E, Faure E, Salizzoni P, Le Romancer M, Severi G, Mancini FR, Leffondre K, Dossus L, Fervers B. Long-term airborne dioxin exposure and breast cancer risk in a case-control study nested within the French E3N prospective cohort. Environ Int. 2019 Mar;124:236-248. doi: 10.1016/j.envint.2019.01.001. Epub 2019 Jan 16.
- Results publication: PubMed 18469262Lajous M, Boutron-Ruault MC, Fabre A, Clavel-Chapelon F, Romieu I. Carbohydrate intake, glycemic index, glycemic load, and risk of postmenopausal breast cancer in a prospective study of French women. Am J Clin Nutr. 2008 May;87(5):1384-91. doi: 10.1093/ajcn/87.5.1384.
- Results publication: PubMed 36809347Fournier A, Cairat M, Severi G, Gunter MJ, Rinaldi S, Dossus L. Use of menopausal hormone therapy and ovarian cancer risk in a French cohort study. J Natl Cancer Inst. 2023 Jun 8;115(6):671-679. doi: 10.1093/jnci/djad035.
- Results publication: PubMed 12800205Paoletti X, Clavel-Chapelon F. Induced and spontaneous abortion and breast cancer risk: results from the E3N cohort study. Int J Cancer. 2003 Aug 20;106(2):270-6. doi: 10.1002/ijc.11203.
- Results publication: PubMed 11875733Clavel-Chapelon F; E3N-EPIC Group. Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br J Cancer. 2002 Mar 4;86(5):723-7. doi: 10.1038/sj.bjc.6600124.
- Results publication: PubMed 15551359Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005 Apr 10;114(3):448-54. doi: 10.1002/ijc.20710.
- Results publication: PubMed 18323549Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol. 2008 Mar 10;26(8):1260-8. doi: 10.1200/JCO.2007.13.4338.
- Derived from this study: PubMed 41956708Dusser P, Nguyen Y, Perrin C, Frenoy P, Mariette X, Boutron-Ruault MC, Severi G, Salliot C, Seror R. Birth length and perinatal exposures and rheumatoid arthritis risk in the E3N cohort. RMD Open. 2026 Apr 9;12(2):e006415. doi: 10.1136/rmdopen-2025-006415.
- Derived from this study: PubMed 41360603Dusser P, Nguyen Y, Perrin C, Frenoy P, Mariette X, Boutron-Ruault MC, Varraso R, Severi G, Salliot C, Seror R. Early-life animal and farming exposures and the risk of rheumatoid arthritis: findings from the E3N French cohort study. RMD Open. 2025 Dec 7;11(4):e005954. doi: 10.1136/rmdopen-2025-005954.
- Derived from this study: PubMed 40719276Auguste A, Jansana A, Freisling H, Ferrari P, Laouali N, Severi G, Kvaskoff M. Impact of Hypertension on Cancer Stage at Diagnosis Among French Women: The E3N Prospective Cohort. Cancer Med. 2025 Aug;14(15):e71021. doi: 10.1002/cam4.71021.
- Derived from this study: PubMed 40490966Klu YE, Amazouz H, Canonico M, Guenel P, Kvaskoff M, Severi G, Radoi L, Auguste A. Association Between Hormonal Factors and Risk of Lung and Upper Aerodigestive Tract Cancer in French Women: The E3N Prospective Cohort Study. Cancer Rep (Hoboken). 2025 Jun;8(6):e70223. doi: 10.1002/cnr2.70223.
- website of the studyLink provided by the sponsor.
Related trials for Breast Cancer
Not yet recruiting
Decision Support for Chemoprevention
Breast Cancer
Active, not recruiting
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Not yet recruitingPhase 2
The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
Doxorubicin Induced Cardiotoxicity, Doxorubicin Induced Cardiomyopathy
Not yet recruiting
Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer
Breast Cancer
Active, not recruitingObservational study
Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy
Breast Cancer, Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gianluca Severi, PhD study director
INSERM (Institut National de la Sante et de la Recherche Medicale)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer and Colo-rectal Cancer, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 25 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Anthropometric measurements (time frame: From 1990 until now). The study lists 17 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03285230, which also lists 21 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2026.